GLP-1 drugsHumans11 adultsCohort study

Fat and lean mass changes during incretin-based therapy with structured exercise and nutritional support: A retrospective real-world pilot study

Graphical abstract from Obesity Pillars — Graphical abstractKucuk Yetgin et al.

Obesity Pillars

The paper

Meral Küçük Yetgin, Nana Gletsu‐Miller, Robert F. Chapman,

Eithan Gelber, John Snyder, Donny Gregg,

Dustin C. Nabhan

Indiana University Bloomington · Apeiron Biologics (Austria)

Obesity Pillars · 19 Sep 2026

doi.org/10.1016/j.obpill.2026.100335 PubMed 42820241

GLP-1 agonists plus SGLT2 inhibitors lower kidney events in CKD
Diabetes, Obesity & Metabolism · 4 Oct 2026
SGLT2 inhibitors link to lower dementia risk than GLP-1 drugs
Diabetes & Vascular Disease Research · 4 Oct 2026
SGLT2 inhibitors match GLP-1 drugs for overall kidney outcomes
Clinical Journal of the American Society of Nephrology · 4 Oct 2026
GLP-1 receptor agonists link to lower stroke and Alzheimer risk
Neurology Genetics · 4 Oct 2026